total revenue from sales, up from 18.8% during the corresponding period last year. Such significant increase resulted mainly from consolidations of ICUK’s financial performance and position since the 4th
from consolidations of ICUK’s financial performance and position since the 4th quarter of 2016. SG&A expenses Unit: THB million 3-month period ending Change 6-month period ending Change 30 Jun 16 30 Jun
resulted mainly from consolidations of ICUK’s financial performance and position since the 4th quarter of 2016. SG&A expenses 3-month period ending Change 9-month period ending Change Unit: THB million 30
mainly from consolidations of ICUK’s financial performance and position since the 4th quarter of 2016. Selling expenses amounted to THB 2,379 million up by THB 916 million or 62.7% representing 18.4% of
production volume and higher overall earnings as assets acquired in 2018 and the consolidations of 2018/19 were successfully integrated. These include acquisitions of PTA Portugal, PET (Egypt and Brazil), and
benefitted from higher production volume and higher overall earnings as assets acquired in 2018 and the consolidations of 2018/19 were successfully integrated. These include acquisitions of PTA Portugal, PET
opportunities, including mergers and acquisitions (M&A), to reinforce its business plan and long-term growth strategy. The acquisition of GLAND marks an important step for CPN towards becoming the leader in mixed
targeted increased sales revenues and also to enable the achievement of targeted net profits. Additionally, there are also other supporting factors for Inorganic Growth through possible mergers and
the events above. CPN is currently in the process of reviewing the investment plan to develop the assets of GLAND. CPN constantly looks for new investment opportunities, including mergers and